Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Globe Newswire (Wed, 11-Feb 7:27 AM ET)
Market Chameleon (Mon, 12-Jan 6:53 AM ET)
Geron Corporation Provides 2026 Financial Guidance
Globe Newswire (Mon, 12-Jan 8:00 AM ET)
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 18-Dec 4:30 PM ET)
Globe Newswire (Thu, 11-Dec 8:00 AM ET)
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Geron trades on the NASDAQ stock market under the symbol GERN.
As of February 17, 2026, GERN stock price climbed to $1.80 with 19,914,121 million shares trading.
GERN has a beta of 1.45, meaning it tends to be more sensitive to market movements. GERN has a correlation of 0.14 to the broad based SPY ETF.
GERN has a market cap of $1.15 billion. This is considered a Small Cap stock.
Last quarter Geron reported $47 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-6 million and exceeded earnings estimates by $.01.
In the last 3 years, GERN traded as high as $5.34 and as low as $1.04.
The top ETF exchange traded funds that GERN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
GERN has underperformed the market in the last year with a return of -35.5%, while SPY returned +13.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in GERN shares. However, GERN has outperformed the market in the last 3 month and 2 week periods, returning +56.5% and +31.4%, while SPY returned +1.9% and -1.3%, respectively. This indicates GERN has been having a stronger performance recently.
GERN support price is $1.58 and resistance is $1.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GERN shares will trade within this expected range on the day.